Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock

by · The Cerbat Gem

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Ventures L.P. 5Am sold 52,317 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $6.85, for a total value of $358,371.45. Following the transaction, the insider directly owned 2,783,781 shares of the company’s stock, valued at approximately $19,068,899.85. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Entrada Therapeutics Trading Up 1.2%

Shares of NASDAQ TRDA traded up $0.08 during midday trading on Monday, reaching $6.95. The company’s stock had a trading volume of 411,770 shares, compared to its average volume of 464,800. The stock has a 50 day simple moving average of $6.86 and a 200-day simple moving average of $9.68. The stock has a market capitalization of $270.63 million, a price-to-earnings ratio of -1.76 and a beta of -0.26. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. As a group, equities analysts anticipate that Entrada Therapeutics, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TRDA. Weiss Ratings cut shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Guggenheim lowered their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Roth Capital set a $10.00 target price on Entrada Therapeutics in a research report on Friday, May 8th. Finally, HC Wainwright lowered Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $17.50.

Get Our Latest Analysis on TRDA

Institutional Investors Weigh In On Entrada Therapeutics

Several hedge funds have recently modified their holdings of TRDA. State of Wyoming bought a new stake in Entrada Therapeutics during the 2nd quarter worth $37,000. Russell Investments Group Ltd. raised its position in Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after purchasing an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics during the second quarter valued at about $68,000. Jain Global LLC acquired a new stake in shares of Entrada Therapeutics during the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Entrada Therapeutics during the second quarter worth about $72,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

Featured Stories